The estimated Net Worth of Vicente Jr Anido is at least $8.54 Milione dollars as of 9 September 2019. Vicente Anido owns over 26,250 units of Aerie Pharmaceuticals Inc stock worth over $3,013,873 and over the last 11 years he sold AERI stock worth over $0. In addition, he makes $5,529,670 as Chairman of the Board e Chief Executive Officer at Aerie Pharmaceuticals Inc.
Sign up
Vicente Anido AERI stock SEC Form 4 insiders trading
Vicente has made over 4 trades of the Aerie Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 26,250 units of AERI stock worth $499,013 on 9 September 2019.
The largest trade he's ever made was exercising 150,000 units of Aerie Pharmaceuticals Inc stock on 6 June 2018 worth over $441,000. On average, Vicente trades about 11,054 units every 93 days since 2013. As of 9 September 2019 he still owns at least 197,631 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Vicente Anido stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vicente Anido biography
Dr. Vicente Anido Jr., Ph.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Anido is the former President, Chief Executive Officer and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as General Partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013, Depomed, Inc. from February 2013 to May 2016 and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008, Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.
What is the salary of Vicente Anido?
As the Chairman of the Board e Chief Executive Officer of Aerie Pharmaceuticals Inc, the total compensation of Vicente Anido at Aerie Pharmaceuticals Inc is $5,529,670. There are no executives at Aerie Pharmaceuticals Inc getting paid more.
How old is Vicente Anido?
Vicente Anido is 67, he's been the Chairman of the Board e Chief Executive Officer of Aerie Pharmaceuticals Inc since 2013. There are 4 older and 16 younger executives at Aerie Pharmaceuticals Inc. The oldest executive at Aerie Pharmaceuticals Inc is Gerald Cagle, 75, who is the Independent Director.
What's Vicente Anido's mailing address?
Vicente's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.
Insiders trading at Aerie Pharmaceuticals Inc
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra e Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
What does Aerie Pharmaceuticals Inc's logo look like?
Complete history of Vicente Anido stock trades at Aerie Pharmaceuticals Inc
Aerie Pharmaceuticals Inc executives and stock owners
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Vicente Anido,
Chairman of the Board, Chief Executive Officer -
Thomas Mitro,
President, Chief Operating Officer -
John LaRocca,
General Counsel and Assistant Secretary -
Richard Rubino,
Chief Financial Officer, Treasurer, Secretary -
Casey Kopczynski,
Co-Founder, Chief Scientific Officer -
Raj Kannan,
CEO, Principal Financial Officer & Director -
Thomas A. Mitro,
Pres & COO -
Dr. Casey C. Kopczynski,
Co-Founder & Chief Scientific Officer -
John W. LaRocca Esq.,
Gen. Counsel & Sec. -
Dr. David A. Hollander M.B.A., M.D.,
Chief R&D Officer -
Benjamin McGraw,
Lead Independent Director -
Gerald Cagle,
Independent Director -
Julie McHugh,
Independent Director -
David Gryska,
Independent Director -
Mechiel Du Toit,
Independent Director -
Richard Croarkin,
Independent Director -
Dr. Benjamin F. McGraw III, J.D., Pharm.D.,
Exec. Chairman -
Peter McDonnell,
Director -
David Hollander,
Chief Research and Development Officer -
Nina Ohara,
Director of Marketing -
Craig R. Skenes,
Head of Bus. Devel. -
Marvin J. Garrett,
Head of Regulatory Affairs & Quality Assurance -
Wanda Francies,
Head of HR -
Jeffrey M. Calabrese CPA,
VP of Fin. & Principal Accounting Officer -
Dr. Michelle Senchyna Ph.D.,
Head of Clinical Devel. & Operations -
Peter F. Lang,
Chief Financial Officer -
Carolyn McAuliffe,
Sr. Director of Communications -
Evan Hockman,
VP of Sales -
Tad Heitmann,
Head of Communications -
Andrew Allen,
Chief Compliance Officer -
Ami Bavishi,
Director of Investor Relations -
Jeffrey Calabrese,
Director of Accounting -
Toit Michael Du,
Director -
Murray A Goldberg,
Director -
Capital Management Ii, Llc ...,
-
Geoffrey M Duyk,
Director -
Capital Management Ii, Llc ...,
-
Capital Management Ii, Llc ...,
-
James E Deerfield Mgmt L.P....,
-
Anand Healy Jamespowell Mic...,
-
James V Mazzo,
Director -
Group Holdings (Sbs) Adviso...,
-
Brian Levy,
Chief Medical Officer -
Venture Partners Vii L P So...,
-
Iv, L.P.Acmp Iv Llcjanney D...,
-
Lifesciences Ii, L.P.Clarus...,
-
Iv, L.P.Janney Danielnohra ...,
-
Anand Mehra,
Director -
Peter Frederick Lang,
Chief Financial Officer -
Capital Management Iv, Llc ...,
-
Capital Management Ii, Llc ...,
-
Jeffrey Calabrese,
Vice President of Finance -
Christopher Staten,
Interim CFO -
Raj Kannan,
Chief Executive Officer -
Kathleen Mcginley,
CHRO & VP, Corp Services